Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y 1 , Y 2 , Y 4 and Y 5 ). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
Introduction
Neuropeptide Y (NPY) is a 36 amino acids peptide, which was first identified from porcine brain in 1982 [1] . It belongs to the family of pancreatic polypeptides (PPs), and shows a high sequence similarity to PP and peptide YY (PYY) [2] . NPY is widely distributed in the central nervous system and periphery, involving in a variety of essential physiological key functions, such as feeding, memory, anxiety and energy homeostasis [3, 4] . In human, these functions are mediated by different NPY or the so called Y receptor subtypes: Y 1 , Y 2 , Y 4 , Y 5 and y 6 , which all belong to the family of G-protein coupled receptors (GPCR). The activation of GPCR leads to the inhibition of adenylyl cyclase and cyclic adenosine monophosphate accumulation, and the modulation of Ca 2þ and K þ channels [5, 6] .
In the past decades, plenty of basic research has been done to explore the expression and related function of NPY receptors in human (Table 1) . Recently, NPY receptors have attracted great attention because of its over-expression in a variety of human cancers, such as breast carcinomas and neuroblastomas [7] . This makes the NPY receptors truly attractive as promising target for cancer imaging and therapy [8] . This review summarizes the current knowledge on the expression incidence and density of NPY receptors in various cancers, the selective ligands for different NPY receptors subtype and their application in cancer diagnosis and treatment.
NPY Receptors Expression in Human Cancers
Recently, more and more evidence suggests that NPY and NPY receptors play an important role in human cancers. The Reubi group has made lots of efforts on the identification of NPY receptors expression in various human tumors by using in vitro receptor autoradiography [7] . It has been found that the two best-investigated Y 1 and Y 2 receptors were over-expressed in breast, adrenal gland, renal cell, ovarian and brain tumors ( Table 2 ). The in vitro receptor autoradiography study indicated that Y 1 receptor was overexpressed in more than 85% primary human breast tumors and 100% of breast cancer derived metastases, whereas normal human breast expressed Y 2 receptor preferentially. Interestingly, [29] . In this case, breast cancer has attracted lots of attention, because of its extremely high expression incidence and density compared with all other NPY receptors positive tumors. Moreover, ovarian malignancies [30] , adrenal cortical tumors [31] , glioblastomas [32] and nephroblastomas [33] also showed higher Y 1 or Y 2 receptor incidence and moderate density. In addition, Y 1 receptor has also been found in prostate cancer cell lines [34] , but was not detected in non-small cell lung, prostate and colorectal cancers. Besides aforementioned tumors, tumor-associated blood vessels also express Y 1 receptor. For instance, Y 1 receptor has been found in the blood vessels of renal cell and adrenal cortical tumors, but rare in ovarian tumors [30, 31, 33] . Surprisingly, Y 1 receptor has also been identified in the blood vessel of tumors which do not express Y receptor on tumor cells, such as renal cell and gastrointestinal stromal tumors [35] . Hence, the tumoral blood supply might be mediated by the activation of NPY receptors through the endogenous NPY released from intratumoral nerve fibers or tumor cells themselves.
Additionally, it was reported that NPY or its analogs could induce dose-dependent inhibition in the growth of Y 1 -expressing human SK-N-MC and MCF-7 tumor cells [29, 36] , but promote the growth of PC3 tumor cells [34] , suggesting that NPY plays its function in cancers via NPY receptors.
Selective ligands for NPY receptors targeting
As it has been previously described, the expression of NPY receptors subtype varies according to the tumors, which makes the design of subtype selective ligands truly attractive for specific tumor targeting. The Beck-Sickinger group has made many efforts to get the subtype selectivity of NPY receptors [40] . [51] . However, most of them are receptor antagonists, which show high affinity but are not able to activate the receptor, because Y 1 receptor internalization is only induced by agonists. Due to receptor internalization is important for the improvement of the tumor to back ground ratio in imaging, and necessary for receptor-mediated targeted drug delivery to tumor cells, the agonists are required for either cancer imaging or therapy. Until now, it was reported that Y 1 [52] [53] [54] [55] [56] , Y 2 [57] , Y 4 [58] and Y 5 [59] receptors were able to internalize upon agonist exposure, and the agonist-induced receptor internalization of NPY receptor subtypes critically depends on third intracellular loop and C-terminus [53] .
Application in cancer imaging and therapy
Due to the high expression of NPY receptors in various cancers, their selective ligands could be used as potential targeted molecules for specific cancer imaging and therapy. Until now, most of the studies have mainly focused on the scintimammography and positron emission tomography (PET) imaging for cancers (Table 3) . For instance, Khan et al. [60] from Beck-Sickinger group has designed and synthesized two NPY-derived Y 1 receptor ligands conjugated with 99m Tc in the position of the chelator for tumor labeling. The in vitro and in vivo uptake of developed ligands has also been investigated in breast cancer patients. The results indicated that the over-expressed Y 1 receptor in human breast cancer provided a chance for tumor targeting by using selective Y 1 receptor ligand, and could be further extended to a tumor-specific targeted therapy by using NPY analogs as a carrier for chemotherapeutics. Hofmann et al. [61] 4 ]BVD15 with different metal radioisotopes needs to be evaluated. Moreover, Shrivastava et al. [62] has developed a novel BVD15 analog t-BBN/BVD15-DO3A, which was able to target both the GRP-expressing T-47D cells and Y 1 receptor-expressing MCF-7 cells. In the next step, t-BBN/BVD15-DO3A will be labeled with 68 Ga for imaging and
177
Lu for radiotherapy, and the in vitro cell binding and in vivo tumor animal studies will also need to be conducted.
Although selective NPY receptor ligands have been widely applied in cancer imaging by scintimammography and PET, only few literatures reported about the NPY receptor-based drug design for cancer therapy. Li et al. from Wu group has developed an Y 1 receptor-based nanoparticulate drug delivery system to deliver anticancer drug doxorubicin into the breast cancer cells, and evaluated its potential for breast cancer therapy. In this study, a high selective Y 1 was used as a targeted molecule to conjugate with drug-loaded albumin nanoparticles. In vitro cellular uptake experiment showed that the PNBL-NPY could actively recognize and bind to the Y 1 receptor that was significantly overexpressed on the breast cancer cells. Further cell viability test indicated that the PNBL-NPY modified drug-loaded nanoparticles were able to be transferred into the 
Conclusion and Perspectives
Since NPY was first identified from porcine brain in 1982, NPY receptors have been extensively studied to explore its expression and related functions in human. Surprisingly, the over-expression of NPY receptors has been found in human cancers corresponding to different Y subtype receptors. It makes this multireceptor/multiligand system truly attractive for targeted cancer imaging and therapy. This is practically true for breast cancer, which is not only due to its highest incidence and density in breast tumors but also because of the different subtypes expression between breast tumors (Y 1 receptor) and normal breast tissues (Y 2 receptor). In previous report, most of the NPY receptor-based cancer imaging or therapy is mainly focused on the breast cancer, but it could also be explored to many other tumors such as prostate, ovary, pancreas and brain tumors. Moreover, the co-expression of Y receptor in tumors and tumor-associated blood vessels makes it a promising target for dual-targeted cancer treatment, because the tumor-associated blood vessels as the main components of tumor microenvironment could provide oxygen and nutrition for the tumor growth [64] . As we know that, successful receptor-mediated tumor imaging and therapy asks not only suitable peptides to target the corresponding receptor but also requires receptor internalization to transfer the receptor bound drug into the tumor cells. For NPY receptors, the receptor subtypes internalization is induced only by agonists rather than antagonists, e.g. Y 1 , Y 2 , Y 4 and Y 5 receptors are able to internalize upon agonist exposure. Hence, developing more potent selective ligands (agonists) will be a focus of interest for specific tumor targeting in the future.
Although selective tumor targeted imaging in breast cancer patients has been achieved successfully by using NPY analogs that specifically binding Y 1 subtype receptors, there is still a lack of therapeutics for clinical cancer therapy. Besides the reported Y receptor-based nanomedicine and radiopharmaceuticals, peptide-drug conjugate might be another choice to make Y receptor-based therapeutics as promising candidates for cancer therapy in clinic [65, 66] .
